Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report

A A Pract. 2019 Jul 15;13(2):69-73. doi: 10.1213/XAA.0000000000000994.

Abstract

The recommended duration of dual antiplatelet therapy after drug-eluting stent placement presents a dilemma for patients with recent stenting who require urgent or emergency noncardiac surgery. We present the case of a patient with recent drug-eluting stent placement (<6 months) on dual antiplatelet therapy who underwent successful emergency cervical spine surgery with antiplatelet therapy bridged using cangrelor, an intravenous P2Y12 inhibitor antiplatelet agent. Our experience illustrates the multidisciplinary approach to a patient with high thrombotic and bleeding risk who underwent neurosurgery off both aspirin and a P2Y12 inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Accidental Falls
  • Accidental Injuries / etiology
  • Accidental Injuries / surgery*
  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Aged
  • Cervical Cord / injuries
  • Cervical Cord / surgery*
  • Diskectomy
  • Drug-Eluting Stents / adverse effects
  • Humans
  • Male
  • Platelet Aggregation Inhibitors / adverse effects*
  • Spinal Fusion

Substances

  • Platelet Aggregation Inhibitors
  • Adenosine Monophosphate
  • cangrelor